ATOS

Company Overview — What Does ATOSSA THERAPEUTICS, INC. Do?

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. ATOSSA THERAPEUTICS, INC. (ATOS) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Steven C. Quay and employs approximately 8 people, headquartered in Seattle, Washington. With a market capitalization of $44M, ATOS is one of the notable companies in the Healthcare sector.

ATOSSA THERAPEUTICS, INC. (ATOS) Stock Rating — Hold (April 2026)

As of April 2026, ATOSSA THERAPEUTICS, INC. receives a Hold rating with a composite score of 32.6/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.ATOS ranks #1,700 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ATOSSA THERAPEUTICS, INC. ranks #162 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ATOS Stock Price and 52-Week Range

ATOSSA THERAPEUTICS, INC. (ATOS) currently trades at $4.94. The stock lost $0.04 (0.8%) in the most recent trading session. The 52-week high for ATOS is $7.56, which means the stock is currently trading -34.7% from its annual peak. The 52-week low is $0.53, putting the stock 828.4% above its annual trough. Recent trading volume was 30K shares, suggesting relatively thin trading activity.

Is ATOS Overvalued or Undervalued? — Valuation Analysis

ATOSSA THERAPEUTICS, INC. (ATOS) carries a value factor score of 11/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.07x, versus the sector average of 2.75x.

At current multiples, ATOSSA THERAPEUTICS, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

ATOSSA THERAPEUTICS, INC. Profitability — ROE, Margins, and Quality Score

ATOSSA THERAPEUTICS, INC. (ATOS) earns a quality factor score of 18/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -78.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -65.3% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ATOS Debt, Balance Sheet, and Financial Health

ATOSSA THERAPEUTICS, INC. has a debt-to-equity ratio of 21.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.53x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $52M.

ATOS has a beta of 2.24, meaning it is more volatile than the broader market — a $10,000 investment in ATOS would be expected to move 124.1% more than the S&P 500 on any given day. The stability factor score for ATOSSA THERAPEUTICS, INC. is 12/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

ATOSSA THERAPEUTICS, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, ATOSSA THERAPEUTICS, INC. reported revenue of $0 and earnings per share (EPS) of $-4.04. Net income for the quarter was $-31M. Operating income came in at $-32M.

In FY 2025, ATOSSA THERAPEUTICS, INC. reported revenue of $0 and earnings per share (EPS) of $-4.04. Net income for the quarter was $-35M. Operating income came in at $-37M.

In Q3 2025, ATOSSA THERAPEUTICS, INC. reported revenue of $0 and earnings per share (EPS) of $-0.07. Net income for the quarter was $-9M. Operating income came in at $-9M.

In Q2 2025, ATOSSA THERAPEUTICS, INC. reported revenue of $0 and earnings per share (EPS) of $-0.07. Net income for the quarter was $-8M. Operating income came in at $-9M.

Over the past 8 quarters, ATOSSA THERAPEUTICS, INC. has experienced revenue contraction from $0 to $0. Investors analyzing ATOS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ATOS Dividend Yield and Income Analysis

ATOSSA THERAPEUTICS, INC. (ATOS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ATOS Momentum and Technical Analysis Profile

ATOSSA THERAPEUTICS, INC. (ATOS) has a momentum factor score of 80/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 20/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ATOS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ATOSSA THERAPEUTICS, INC. (ATOS) ranks #162 out of 838 stocks based on the Blank Capital composite score. This places ATOS in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ATOS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ATOS vs S&P 500 (SPY) comparison to assess how ATOSSA THERAPEUTICS, INC. stacks up against the broader market across all factor dimensions.

ATOS Next Earnings Date

No upcoming earnings date has been announced for ATOSSA THERAPEUTICS, INC. (ATOS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ATOS? — Investment Thesis Summary

ATOSSA THERAPEUTICS, INC. presents a balanced picture with arguments on both sides. The quality score of 18/100 flags below-average profitability. The value score of 11/100 indicates premium valuation. Price momentum is positive at 80/100, suggesting the trend favors buyers. High volatility (stability score 12/100) increases portfolio risk.

In summary, ATOSSA THERAPEUTICS, INC. (ATOS) earns a Hold rating with a composite score of 32.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ATOS stock.

Related Resources for ATOS Investors

Explore more research and tools: ATOS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ATOS head-to-head with peers: ATOS vs AZN, ATOS vs SLGL, ATOS vs VMD.